Prevalence of S282T mutation in different genotypes of hepatitis C virus from DAA-treated naïve Chinese patients who were chronically infected with HCV.
Although direct-acting antiviral agents (DAAs) for treating hepatitis C virus (HCV) infection have not yet been approved for clinical application at present in China, the development trend is irresistible. DAAs-containing therapeutic regimens have been approved and others are also under development worldwide. In vitro studies have shown that S282T mutation in the NS5B region of HCV is involved in DAAs resistance. The aim of this study was to investigate naturally occurring resistance mutation of S282T in different genotypes of HCV from DAA-treated naïve Chinese patients who were chronically infected with HCV. 250 Chinese patients chronically infected with HCV were enrolled in this study. All subjects were naïve to DAAs. Direct sequencing of HCV NS5B region was performed in all enrolled patients. 70.4% (176/250) cases were infected with HCV genotype 1b, 19.2% (47/250) were 2a, 4.0% (11/250) were 6a, 3.6% (10/250) were 3b, 1.6% (4/250) were 1a and 1.2% (3/250) were 3a. Genotype 4, 5 and 7 were not observed. The S282T mutation was not found in any of the cases. The results showed that the S282T mutation was not prevalent in DAA-treated naïve Chinese patients who were chronically infected with HCV.